SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

Strona główna・Stock List・Bayer AG

Bayer AG

Closed

SectorFinance

34.7 1.76

Buy Sell

Overview

Share price change

24h

Current

Min

33.88

Max

34.75

Key metrics
By Trading Economics
Income	6.5B 2.8B
Sales	2B 13B
EPS	2.812
Dividend yield	0.3
Profit margin	20.612
Employees	87,757
EBITDA	2.3B 4.4B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+41.05% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.30% 4.65%
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-1.9B 35B
Previous open	32.94
Previous close	34.7

News Sentiment

By Acuity

22%

78%

41 / 439 Ranking in Finance

Bayer AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 cze 2026, 11:21 UTC

Major Market Movers

Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement

12 maj 2026, 11:24 UTC

Earnings

Major Market Movers

Bayer Shares Climb After Earnings Beat Expectations

12 maj 2026, 06:10 UTC

Earnings

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 maj 2026, 10:51 UTC

Acquisitions, Mergers, Takeovers

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 maj 2026, 07:01 UTC

Acquisitions, Mergers, Takeovers

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2 cze 2026, 11:22 UTC

Market Talk

Bayer Hit by New Roundup Legal Jitters -- Market Talk

29 maj 2026, 08:15 UTC

Market Talk

Earnings

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

29 maj 2026, 07:42 UTC

Market Talk

Bayer Can Still Take Hit if Litigation Strategy Fails -- Market Talk

12 maj 2026, 12:05 UTC

Hot Stocks

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 maj 2026, 10:51 UTC

Hot Stocks

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 maj 2026, 09:08 UTC

Hot Stocks

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 maj 2026, 05:38 UTC

Earnings

Bayer Backs 2026 Outlook Adjusted for Currency

12 maj 2026, 05:36 UTC

Earnings

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 maj 2026, 05:36 UTC

Earnings

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 maj 2026, 05:36 UTC

Earnings

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 maj 2026, 05:35 UTC

Earnings

Bayer 1Q Adj EPS EUR2.71

12 maj 2026, 05:34 UTC

Earnings

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 maj 2026, 05:34 UTC

Earnings

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 maj 2026, 05:34 UTC

Earnings

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 maj 2026, 05:34 UTC

Earnings

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 maj 2026, 05:33 UTC

Earnings

Bayer 1Q EBIT EUR3.53B

12 maj 2026, 05:32 UTC

Earnings

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 maj 2026, 05:32 UTC

Earnings

Bayer 1Q Net Pft EUR2.76B

12 maj 2026, 05:31 UTC

Earnings

Bayer 1Q Sales EUR13.405B

12 maj 2026, 05:31 UTC

Earnings

Bayer Backs 2026 View

6 maj 2026, 06:34 UTC

Acquisitions, Mergers, Takeovers

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 maj 2026, 06:33 UTC

Acquisitions, Mergers, Takeovers

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 maj 2026, 06:33 UTC

Acquisitions, Mergers, Takeovers

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 maj 2026, 06:32 UTC

Acquisitions, Mergers, Takeovers

Bayer to Pay $300M Upfront

6 maj 2026, 06:32 UTC

Acquisitions, Mergers, Takeovers

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

41.05% upside

12 Months Forecast

Average 49.55 EUR 41.05%

High 56 EUR

Low 40 EUR

Based on 12 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Bayer AG - Dist in the past 3 months.

Sentiment

By Acuity

41 / 439 Ranking in Finance

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.